CIP2A Antibody

Western Blot: CIP2A Antibody [NB100-68264]

Western Blot: CIP2A Antibody [NB100-68264] - Detection of Human CIP2A on HeLa whole cell lysate using NB100-68264. CIP2A was also immunoprecipitated by rabbit anti-CIP2A antibody NB100-68263.

Western Blot: CIP2A Antibody [NB100-68264]

CIP2A-Antibody-Knockdown-Validated-NB100-68264-img0004.jpg

Western Blot: CIP2A Antibody [NB100-68264] -

Western Blot: CIP2A Antibody [NB100-68264] - HPV-16E7 & -58E7 upregulated CIP2A mRNA & protein levels in PHKs(A) Western blot analysis of CIP2A protein level in PHKs expressing HPV-16E7, -58E7, -6E7; & (B) Quantification. (C) qRT-PCR analysis of CIP2A mRNA level in PHKs expressing HPV-16E7, -58E7, -6E7. (D) Western blot analysis of CIP2A protein level in PHKs expressing HPV-16E7 & 16E7 mutants L22A & C24G. Babe, vector control. *, P < 0.05; **, P < 0.01; & ***, P < 0.001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/25650660), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CIP2A Antibody [NB100-68264] -

Western Blot: CIP2A Antibody [NB100-68264] - Silencing CIP2A caused decreased Cdk1 & Cdk2 proteins in 16E6‐expressing cells. A, Western blot analysis of CIP2A, Cdk4, Cdk6, cyclin D1, Cdk1, Cdk2, cyclin B1, cyclin A2 & cyclin E1 protein levels in cells expressing HPV‐16E6 transfected with CIP2A siRNA & then treated with PBS or 10 μg/mL bleomycin for 24 h. A representative of 3 independent experiments is shown. B, Quantification of all cell cycle‐related proteins. Data from 3 experiments are summarized. C, Relative mRNA levels of all cell cycle‐related genes determined by qRT‐PCR. Data from 3 experiments are summarized. *, P < .05; **, P < .01 Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29893470), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CIP2A Antibody [NB100-68264] -

Western Blot: CIP2A Antibody [NB100-68264] - Inhibition of Cdk1 & Cdk2 by CIP2A knockdown in cervical cancer SiHa cells caused G1 arrest. A, Western blot analysis of 16E6, p53 & CIP2A after HPV‐16E6 knockdown in cervical cancer SiHa cells. B, Protein expression of CIP2A, B‐Myb, Cdk1 & Cdk2 in SiHa cells after CIP2A knockdown. Data from a representative of 3 experiments are shown. C, Flow cytometric analysis of SiHa cells with CIP2A knockdown treated with PBS or bleomycin. A representative flow cytometry of 3 independent experiments is shown. D, Quantification of percentages G1 phase cells. Data from 3 experiments are summarized. *, P < .05 Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29893470), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CIP2A Antibody [NB100-68264] -

Western Blot: CIP2A Antibody [NB100-68264] - Knockdown of CIP2A inhibited cell proliferation & DNA synthesis of HPV-16E7-expressing cells(A) Western blot analysis of protein level of 16E7 & CIP2A in RPE1-16E7 cells & (B) with CIP2A siRNA for 48 hr. (C) CCK8 assay of cell proliferation of RPE1-16E7 cells with CIP2A siRNA. (D) Flow cytometry of cells with CIP2A siRNA & labeled with BrdU for 2 hr, then stained with PI & BrdU; & (E), Quantification. Babe, vector control. **, P < 0.01. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/25650660), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CIP2A Antibody [NB100-68264] -

Western Blot: CIP2A Antibody [NB100-68264] - Inhibition of Cdk1 & Cdk2 by CIP2A knockdown in cervical cancer SiHa cells caused G1 arrest. A, Western blot analysis of 16E6, p53 & CIP2A after HPV‐16E6 knockdown in cervical cancer SiHa cells. B, Protein expression of CIP2A, B‐Myb, Cdk1 & Cdk2 in SiHa cells after CIP2A knockdown. Data from a representative of 3 experiments are shown. C, Flow cytometric analysis of SiHa cells with CIP2A knockdown treated with PBS or bleomycin. A representative flow cytometry of 3 independent experiments is shown. D, Quantification of percentages G1 phase cells. Data from 3 experiments are summarized. *, P < .05 Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29893470), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CIP2A Antibody [NB100-68264] -

Western Blot: CIP2A Antibody [NB100-68264] - Inhibition of CIP2A by siRNA impeded cell viability & DNA synthesis in HPV‐16E6–expressing cells. A, Elevated expression of CIP2A protein in 16E6‐expressing RPE1 cells. B, Western blot analysis of CIP2A & p53 proteins after transfection with scrambled siRNA (siCon) or CIP2A siRNA (siCIP2A) for 48 h. A representative of 3 independent experiments is shown. C, Cell viability assay of RPE1‐16E6 cells with CIP2A knockdown. D, Representative flow cytometry of BrdU staining profiles is shown. E, The mean & SD of BrdU‐positive cells from 3 experiments are summarized. **, P < .01. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29893470), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CIP2A Antibody [NB100-68264] -

Western Blot: CIP2A Antibody [NB100-68264] - CIP2A siRNA knockdown caused G1 arrest & decreased Cdk1 & Cdk2 protein levels in E7-expressing cells(A) Flow cytometry of cells expressing 16E7 transfected with CIP2A siRNA for 48 hr, treated with DMSO control or bleomycin (10 μg/mL) for 24 hr, then stained with PI. G1, S & G2 phases are indicated. (B) Western blot analysis of Cdk1, Cdk2, Cyclin A2, Cdk4, Cdk6, Cyclin D1 protein levels in cells expressing HPV-16E7 transfected with CIP2A siRNA. Babe, vector control. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/25650660), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CIP2A Antibody [NB100-68264] -

Western Blot: CIP2A Antibody [NB100-68264] - Knockdown of CIP2A inhibited cell proliferation & DNA synthesis of HPV-16E7-expressing cells(A) Western blot analysis of protein level of 16E7 & CIP2A in RPE1-16E7 cells & (B) with CIP2A siRNA for 48 hr. (C) CCK8 assay of cell proliferation of RPE1-16E7 cells with CIP2A siRNA. (D) Flow cytometry of cells with CIP2A siRNA & labeled with BrdU for 2 hr, then stained with PI & BrdU; & (E), Quantification. Babe, vector control. **, P < 0.01. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/25650660), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CIP2A Antibody [NB100-68264] -

Western Blot: CIP2A Antibody [NB100-68264] - Inhibition of CIP2A by siRNA impeded cell viability & DNA synthesis in HPV‐16E6–expressing cells. A, Elevated expression of CIP2A protein in 16E6‐expressing RPE1 cells. B, Western blot analysis of CIP2A & p53 proteins after transfection with scrambled siRNA (siCon) or CIP2A siRNA (siCIP2A) for 48 h. A representative of 3 independent experiments is shown. C, Cell viability assay of RPE1‐16E6 cells with CIP2A knockdown. D, Representative flow cytometry of BrdU staining profiles is shown. E, The mean & SD of BrdU‐positive cells from 3 experiments are summarized. **, P < .01. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29893470), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CIP2A Antibody [NB100-68264] -

Western Blot: CIP2A Antibody [NB100-68264] - Regulation of Cdk1 & Cdk2 by CIP2A is dependent on B‐Myb rather than c‐Myc. A, Western blot analysis of CIP2A, c‐Myc, phospho‐S62‐Myc & B‐Myb protein levels in 16E6‐expressing cells after CIP2A knockdown. beta ‐Tubulin was used as a loading control. B, Protein levels of B‐Myb, c‐Myc & phospho‐S62‐Myc in 16E6‐expressing PHKs & (C) RPE1 cells. D, Protein levels of B‐Myb, Cdk1 & Cdk2, CIP2A & p53 in 16E6‐expressing cells after B‐Myb knockdown with siRNA. Data from a representative of 3 experiments are shown. E, Knockdown of B‐Myb down‐regulates Cdk1 & Cdk2 luciferase reporter activities. RPE1 cells were cotransfected with the Cdk1 or Cdk2 promoter‐luciferase constructs & renilla luciferase control plasmid together with B‐Myb siRNA plasmid. Cells were harvested after 48 h, & lysates were assayed for luciferase activity. F, Flow cytometric analysis of 16E6‐expressing cells transfected with B‐Myb siRNA treated with PBS or bleomycin. G1, S & G2 phases are indicated. A representative flow cytometry of 3 independent experiments is shown. G, Quantification of percentages G1 phase cells. Data from 3 experiments are summarized. H, Western blot analysis of B‐Myb, Cdk1 & Cdk2 in B‐Myb–overexpressing CIP2A knockdown cells. Data from a representative of 3 experiments are shown. *, P < .05; ***, P < .001 Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29893470), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CIP2A Antibody [NB100-68264] -

Western Blot: CIP2A Antibody [NB100-68264] - Induction of CIP2A mRNA & protein expression by HPV‐16E6 in PHKs. A, mRNA expression of HPV‐16E6 in PHKs expressing 16E6 & F2V using beta ‐actin as a loading control. B, Protein levels of HPV‐16E6, p53 & p21 in PHKs expressing 16E6 & F2V. Expression of GAPDH was used as a loading control. A representative of 2 independent experiments is shown. C, HPV‐16E6 expression leads to increased protein expression of CIP2A in PHKs. Data from a representative of 3 experiments are shown. D, Data from 3 experiments are summarized. E, Relative CIP2A mRNA expression was determined by qRT‐PCR in the above cells. Data from 3 experiments are summarized. The mean & standard deviation (SD) of 3 independent experiments are shown. Babe, pBabe‐puromycin vector. *, P < .05; **, P < .01; & ***, P < .001 Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29893470), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CIP2A Antibody [NB100-68264] -

Western Blot: CIP2A Antibody [NB100-68264] - Regulation of Cdk1 & Cdk2 by CIP2A is dependent on B‐Myb rather than c‐Myc. A, Western blot analysis of CIP2A, c‐Myc, phospho‐S62‐Myc & B‐Myb protein levels in 16E6‐expressing cells after CIP2A knockdown. beta ‐Tubulin was used as a loading control. B, Protein levels of B‐Myb, c‐Myc & phospho‐S62‐Myc in 16E6‐expressing PHKs & (C) RPE1 cells. D, Protein levels of B‐Myb, Cdk1 & Cdk2, CIP2A & p53 in 16E6‐expressing cells after B‐Myb knockdown with siRNA. Data from a representative of 3 experiments are shown. E, Knockdown of B‐Myb down‐regulates Cdk1 & Cdk2 luciferase reporter activities. RPE1 cells were cotransfected with the Cdk1 or Cdk2 promoter‐luciferase constructs & renilla luciferase control plasmid together with B‐Myb siRNA plasmid. Cells were harvested after 48 h, & lysates were assayed for luciferase activity. F, Flow cytometric analysis of 16E6‐expressing cells transfected with B‐Myb siRNA treated with PBS or bleomycin. G1, S & G2 phases are indicated. A representative flow cytometry of 3 independent experiments is shown. G, Quantification of percentages G1 phase cells. Data from 3 experiments are summarized. H, Western blot analysis of B‐Myb, Cdk1 & Cdk2 in B‐Myb–overexpressing CIP2A knockdown cells. Data from a representative of 3 experiments are shown. *, P < .05; ***, P < .001 Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29893470), licensed under a CC-BY license. Not internally tested by Novus Biologicals.